New lupus treatment shows promise in early human testing
NCT ID NCT07348055
Summary
This early-stage clinical trial is testing a new injection called GR1803 in people with systemic lupus erythematosus (lupus). The study aims to see if the treatment is safe and if it helps control lupus symptoms. Researchers will enroll 44 participants who have active lupus despite current standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.